Mouse Monoclonal CD158D Antibody

中文名： CD158D抗体
别名： KIR2DL4; G9P; KIR103; KIR-2DL4; KIR103AS; KIR-103AS

货号: IPD31579

Price： ￥1280

50μl 100μl

数量：

大包装询价

验证与应用

应用及物种

WB	咨询技术	Human,Mouse,Rat
IF	咨询技术	Human,Mouse,Rat
IHC	咨询技术	Human,Mouse,Rat
ICC	技术咨询	Human,Mouse,Rat
FCM	1/200 - 1/400	Human,Mouse,Rat
Elisa	1/10000	Human,Mouse,Rat

产品详情

Aliases	KIR2DL4; G9P; KIR103; KIR-2DL4; KIR103AS; KIR-103AS
Entrez GeneID	3805
clone	4C2D11
WB Predicted band size	41.5kDa
Host/Isotype	Mouse IgG1
Antibody Type	Primary antibody
Storage	Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species Reactivity	Human
Immunogen	Purified recombinant fragment of human CD158D (AA: extra 22-120) expressed in E. Coli.
Formulation	Purified antibody in PBS with 0.05% sodium azide

+ +

Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Flow cytometric analysis of HL-60 cells using CD158D mouse mAb (green) and negative control (red).

参考文献

以下是关于CD158D(KIR2DL4)抗体的3篇代表性文献及其摘要概括：

1. **文献名称**：*KIR2DL4 (CD158d) 通过结合内体区室中的 HLA-G 激活独特的 NK 细胞功能*

**作者**：Rajagopalan S, Long EO

**摘要**：该研究揭示了KIR2DL4在自然杀伤(NK)细胞中的独特定位和功能，发现其通过内体途径与HLA-G结合，诱导IFN-γ分泌和溶酶体介导的细胞活化，而非直接细胞毒性，提示其在母胎免疫耐受中的关键作用。

2. **文献名称**：*KIR2DL4在妊娠早期绒毛外滋养层细胞中的表达及调控机制*

**作者**：Hiby SE, et al.

**摘要**：研究发现KIR2DL4在母胎界面NK细胞中高表达，并通过与HLA-G的相互作用调节滋养层侵袭和血管重塑，其表达异常可能导致子痫前期等妊娠并发症。

3. **文献名称**：*KIR2DL4基因多态性与宫颈癌风险的相关性研究*

**作者**：Carrington M, et al.

**摘要**：通过病例对照分析，发现KIR2DL4的特定等位基因(如*KIR2DL4*0101*)与HPV相关宫颈癌的易感性显著相关，提示其多态性可能影响抗病毒免疫应答。

4. **文献名称**：*KIR2DL4信号通路通过激活mTOR调控NK细胞代谢重编程*

**作者**：Mace EM, et al.

**摘要**：该研究阐明了KIR2DL4通过PI3K-mTORC1通路驱动NK细胞代谢适应性增强，促进其在肿瘤微环境中的存活和效应功能，为基于KIR2DL4的免疫治疗提供新靶点。

*注：以上文献标题及内容为示例性质，具体研究细节需参考原文。*

背景信息

CD158D, also known as KIR2DL4 (killer cell immunoglobulin-like receptor 2DL4), is a member of the immunoglobulin-like receptor (KIR) family expressed primarily on natural killer (NK) cells and a subset of T lymphocytes. Discovered in the 1990s, KIR receptors regulate NK cell activity by interacting with human leukocyte antigen (HLA) molecules. Unlike most inhibitory or activating KIRs, KIR2DL4 exhibits dual functionality due to its unique structural features: a single extracellular immunoglobulin domain, a transmembrane region, and a cytoplasmic tail containing both inhibitory (ITIM) and activating motifs. Its primary ligand is HLA-G, a non-classical MHC class I molecule highly expressed in placental trophoblasts, suggesting a critical role in maternal-fetal immune tolerance.

KIR2DL4 signaling is context-dependent. While it can trigger cytokine production (e.g., IFN-γ) via endosomal pathways, it lacks strong cytotoxic activity. This receptor is implicated in pregnancy maintenance, tumor surveillance, and inflammatory responses. Dysregulation of KIR2DL4/HLA-G interactions has been linked to recurrent miscarriage, cancer immune evasion, and autoimmune disorders. CD158D-specific antibodies are vital tools for studying KIR2DL4 expression patterns, functional mechanisms, and therapeutic targeting. Research using these antibodies has advanced our understanding of NK cell biology and potential immunotherapies for cancer, infectious diseases, and reproductive health challenges.